Burden of atopic dermatitis in paediatric patients: an international cross-sectional study.

Autor: Weidinger S; Department of Dermatology, Allergology and Venereology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany., Simpson EL; Oregon Health and Science University, Portland, OR, USA., Silverberg JI; Northwestern University Feinberg School of Medicine, Chicago, IL, USA., Barbarot S; Centre Hospitalier Universitaire de Nantes, Nantes, France., Eckert L; Sanofi, Chilly-Mazarin, France., Mina-Osorio P; Regeneron, Tarrytown, NY, USA., Rossi AB; Sanofi, Cambridge, MA, USA., Brignoli L; Kantar - Health Division, Paris, France., Mnif T; Kantar - Health Division, Paris, France., Guillemin I; Sanofi, Chilly-Mazarin, France., Fenton MC; Sanofi, Cambridge, MA, USA., Delevry D; Regeneron, Tarrytown, NY, USA., Chuang CC; Sanofi, Cambridge, MA, USA., Pellan M; Kantar - Health Division, Paris, France., Gadkari A; Regeneron, Tarrytown, NY, USA.

Publikováno v: The British journal of dermatology [Br J Dermatol] 2024 May 17; Vol. 190 (6), pp. 846-857.

GLOBAL PREVALENCE OF PEDIATRIC AND ADULT IGE-MEDIATED FOOD ALLERGIES: Results: FROM THE ASSESS FA STUDY

Autor: Gupta, R., Marvel, J., Tassinari, P., Mnif, T., Hleyhel, M., Vincent, B., Worm, M., Fiocchi, A.

Publikováno v: In Annals of Allergy, Asthma & Immunology November 2023 131(5) Supplement 1:S7-S8

Quantifying the impact of symptomatic acute hepatic porphyria on well-being via patient-reported outcomes: Results from the Porphyria Worldwide Patient Experience Research (POWER) study.

Autor: Dickey A; Division of Pulmonary and Critical Care Medicine, Department of Medicine Massachusetts General Hospital Boston Massachusetts USA., Wheeden K; American Porphyria Foundation Bethesda Maryland USA., Lyon D; American Porphyria Foundation Bethesda Maryland USA., Burrell S; Global Porphyria Advocacy Coalition Durham City UK., Hegarty S; Global Porphyria Advocacy Coalition Durham City UK., Falchetto R; Swiss Society for Porphyria Zürich Switzerland., Williams ER; American Porphyria Foundation Bethesda Maryland USA., Barman-Aksözen J; Swiss Society for Porphyria Zürich Switzerland.; Institute of Laboratory Medicine, Department of Medical Institutes Stadtspital Zürich, Triemli Zürich Switzerland., DeCongelio M; Cerner Enviza (formerly Kantar Health) New York New York USA., Bulkley A; Cerner Enviza (formerly Kantar Health) New York New York USA., Matos JE; Cerner Enviza (formerly Kantar Health) Kansas City Missouri USA., Mnif T; Cerner Enviza (formerly Kantar Health) Paris France., Mora J; Alnylam Pharmaceuticals Cambridge Massachusetts USA., Ko JJ; Alnylam Pharmaceuticals Cambridge Massachusetts USA., Meninger S; Alnylam Pharmaceuticals Cambridge Massachusetts USA., Lombardelli S; Alnylam Pharmaceuticals Maidenhead UK., Nance D; Banner Health Gilbert Arizona USA.

Publikováno v: JIMD reports [JIMD Rep] 2022 Oct 18; Vol. 64 (1), pp. 104-113. Date of Electronic Publication: 2022 Oct 18 (Print Publication: 2023).

POSB353 Quality of Life and Symptom Burden of Paroxysmal Nocturnal Hemoglobinuria Among Patients Receiving C5 Inhibitors in the United States and Europe

Autor: Matos, JE, Mnif, T, Costantino, H, Lehrhaupt, K, Le Calve, P, Sarda, SP, Baver, SB, Fishman, J, Hakimi, Z, Nazir, J, Persson, E, Desgraz, R, Lui, B, Panse, J

Publikováno v: In Value in Health January 2022 25(1) Supplement:S229-S229

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.